ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Xin Xu
Matched on ORCID iD 0000-0001-8838-6646; OpenAlex author ID A5112989765. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2026: 3 papers
Papers 3
- Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. Co-author DOI 10.1038/s41467-026-69695-4↗
- Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC Co-author DOI 10.1038/s41467-026-72371-2↗
- Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1435↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhenkun Lou · 3 shared papers, 2026 · strength 0.84
- Paper Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. DOI 10.1038/s41467-026-69695-4↗
- Paper Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilit… DOI 10.1038/s41467-026-72371-2↗
- Paper Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma. DOI 10.1158/0008-5472.can-25-1435↗
- Changying Li · 3 shared papers, 2026 · strength 0.84
- Paper Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. DOI 10.1038/s41467-026-69695-4↗
- Paper Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilit… DOI 10.1038/s41467-026-72371-2↗
- Paper Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma. DOI 10.1158/0008-5472.can-25-1435↗
- Min Deng · 2 shared papers, 2026 · strength 0.58
- Paper Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. DOI 10.1038/s41467-026-69695-4↗
- Paper Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilit… DOI 10.1038/s41467-026-72371-2↗
- Min Deng · 1 shared paper, 2026 · strength 0.26
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.